Brennan Tara E, Waner Milton, O Teresa M
Vascular Birthmark Institute of New York, New York2Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of New Mexico, Albuquerque3Department of Otolaryngology, Manhattan Eye, Ear and Throat Hospitals, New York, New York4Department of Otolaryngology, Lenox Hill Hospital, New York, New York.
Vascular Birthmark Institute of New York, New York3Department of Otolaryngology, Manhattan Eye, Ear and Throat Hospitals, New York, New York4Department of Otolaryngology, Lenox Hill Hospital, New York, New York.
JAMA Facial Plast Surg. 2017 Jul 1;19(4):282-286. doi: 10.1001/jamafacial.2016.1991.
The current standard of treatment for infantile hemangiomas (IHs) involves initial observation for regression throughout infancy and childhood, with or without medical management with β-blocker medications. Approximately 50% of the lesions respond almost completely to this regimen. However, the remaining 50% of the lesions, especially established focal IHs of the lip, nose, eyelids, forehead, cheek, and scalp, do not regress completely with this regimen or do so leaving a deformity; among these lesions, early surgical management may result in a superior aesthetic and functional outcome.
To identify select focal head and neck lesions of IH that will likely not completely involute with medical management and that are ideal for a 1-stage surgical excision.
DESIGN, SETTING, AND PARTICIPANTS: In this case series, records of infants and children presenting to a tertiary care vascular anomalies center for management of IHs by the senior author were reviewed. Representative examples of focal IHs of the lips, nose, eyelids, cheek, and glabella demonstrating the tissue expansion effect were selected for presentation. Expert opinion based on more than 20 years of experience of the senior surgeon treating more than 2000 patients with focal IH and long-term clinical follow-up is also provided.
Eradication of the IH while restoring aesthetic form and function to the face.
Five examples of patients with focal IHs of the lip, nose, eyelid, cheek, and glabella demonstrating the tissue expander effect who were successfully treated with surgery are presented. The 5 patients with these lesions ranged in age from 3 months to 5 years old, and all of them were female. One of these patients was treated with β-blockers, and another with steroids, with incomplete response to treatment prior to undergoing surgery. The tissue expander effect of a focal IH on adjacent, unaffected tissue facilitated excision of the lesion and primary closure without distortion of anatomical subunits in all 5 of these cases. Improved cosmesis with either improved or unaffected function was demonstrated.
Clinicians should consider early surgical intervention in infants with select focal infantile hemangiomas in lieu of prolonged observation or medical management. The psychological benefit of early removal of these disfiguring lesions has not been quantified, but is subjectively apparent to clinicians and the families of patients. Furthermore, the costs and unknown long-term sequelae of β-blocker medication, which is the current standard of treatment for IHs along with observation for regression, have not yet been quantified but will gain increasing salience in the current medical climate.
目前婴儿血管瘤(IHs)的治疗标准包括在婴儿期和儿童期进行初步观察以等待自行消退,期间可使用或不使用β受体阻滞剂药物进行药物治疗。约50%的病变对此治疗方案反应几乎完全。然而,其余50%的病变,尤其是唇部、鼻部、眼睑、前额、脸颊和头皮等部位已形成的局限性IHs,采用此治疗方案不会完全消退,或消退后会留下畸形;在这些病变中,早期手术治疗可能会带来更好的美学和功能效果。
确定某些不会通过药物治疗完全消退且适合一期手术切除的头颈部局限性IHs病变。
设计、地点和参与者:在这个病例系列中,回顾了由资深作者在三级医疗血管异常中心诊治的婴儿和儿童IHs的记录。选取了唇部、鼻部、眼睑、脸颊和眉间局限性IHs的代表性病例,以展示组织扩张效应。还提供了基于资深外科医生20多年治疗2000多名局限性IHs患者的经验及长期临床随访的专家意见。
根除IHs同时恢复面部的美学形态和功能。
展示了5例唇部、鼻部、眼睑、脸颊和眉间局限性IHs患者,其表现出组织扩张效应,经手术成功治疗。这5例有这些病变的患者年龄在3个月至5岁之间,均为女性。其中1例患者接受过β受体阻滞剂治疗,另1例接受过类固醇治疗,在手术前治疗反应不完全。在所有这5例病例中,局限性IHs对相邻未受影响组织的组织扩张效应便于病变切除及一期缝合,且不使解剖亚单位变形。显示出美容效果改善,功能改善或未受影响。
临床医生应考虑对某些局限性婴儿血管瘤婴儿进行早期手术干预,而非长期观察或药物治疗。早期切除这些毁容性病变的心理益处尚未量化,但临床医生和患者家属主观上明显可见。此外,β受体阻滞剂药物作为目前IHs治疗标准(与观察自行消退一起)的成本和未知的长期后遗症尚未量化,但在当前医疗环境中将变得越来越突出。
5级。